4 unknown, 1 recruiting, 1 suspended. 4 Phase 2, 1 Not applicable, 1 Phase 3.
By phase and status
Follow wang shusen: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
Trilaciclib in Patients With Early-Stage HR-negative Breast Cancer Receiving Adjuvant Chemotherapy Trilaciclib, Epirubicin, Cyclophosphamide - Breast Neoplasms | Phase 2 | Recruiting | 116 | 2023-09-20 | 2023-11-30 |
Fluzoparib in Combination With or Without Camrelizumab for Homologous Recombinant Deficiency (HRD) HER2 Negative Advanced Breast Cancer Fluzoparib, Fluzoparib+Camrelizumab - Advanced HER2 Negative Breast Carcinoma HRD+Breast Cancer | Phase 2 | Suspended | 80 | 2022-11-23 | 2026-03-17 |
Tucidinostat Combined With Metronomic Capecitabine and Endocrine Therapy for Advanced HR-positive, HER2-negative Breast Cancer After CDK4/6 Inhibitor. Tucidinostat, Capecitabine, Endocrine Therapy - Breast Cancer | Phase 2 | Unknown | 73 | 2022-10-03 | 2022-11-04 |
Tucidinostat and Metronomic Capecitabine for Metastatic Triple-negative Breast Cancer:a Multicenter,Open-label, Randomized Controlled, Phase II Clinical Trial Capecitabine, Tucidinostat - Triple Negative Breast Cancer | Phase 2 | Unknown | 126 | 2022-08-01 | 2022-11-04 |
PCI in Advanced Triple Negative Breast Cancer Patients Who Response to 1st Line Chemotherapy prophylactic cranial irradiation - Breast Cancer, Brain Metastasis | Not applicable | Unknown | 326 | 2017-08-01 | 2017-06-01 |
The Efficacy and Safety of PEG-rhG-CSF in Preventing Chemotherapy-induced Neutropenia PEG-rhG-CSF - Breast Cancer | Phase 3 | Unknown | 338 | 2016-05-04 | 2017-06-01 |
Conditions studied
Breast Neoplasms (4) · Triple Negative Breast Neoplasms (2) · Brain Neoplasms (1)
Interventions
Capecitabine (2) · N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide (2) · Anastrozole (1) · Carboplatin (1) · Cyclophosphamide (1) · Docetaxel (1) · Epirubicin (1) · Fulvestrant (1) · Letrozole (1) · Paclitaxel (1) · Trastuzumab (1) · exemestane (1) · fluzoparib (1) · pegylated granulocyte colony-stimulating factor (1) · pertuzumab (1)
Countries
China (6)
Top investigators
Susen Wang, MD (2) · Shusen Wang (1) · Shusen Wang, Doctor (1) · Shusen Wang, MD (1)